Skip to content

PA · IPH.PA

Innate Pharma S.A.

Programmatic access: valuation JSON for this ticker · catalog · agent briefing · agent card. Paid lookups: HTTP 402 then Payment-Authorization, or Authorization: Bearer ic_live_….

Sector
Healthcare · Biotechnology
Headquarters
Marseille 13009

Price at previous close

$1.53

Market cap 141.79M

Price history

The price history chart is shown only to users with a Pro subscription.

InvestorsCraft valuation

Fair value (AI, DCF / IC, Graham) for Innate Pharma S.A. (IPH.PA) is available to Pro members and via the machine API.

  • AI valuation — available
  • Intrinsic / IC value — available
  • Upside vs price — available

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

The valuation history chart is shown only to users with a Pro subscription.

Historic valuation ratios

Pick a category, then toggle metrics to compare.

Historic valuation ratios are shown only to users with a Pro subscription.

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Innate Pharma S.A.

        Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

        CEO
        Jonathan E. Dickinson
        Employees
        181
        Beta
        0.81

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.